4,901 trials
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Healthy · Renal Insufficiency
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Pirtobrutinib — 3450; 2910 nanogram per milliliter (ng/mL)
Healthy
Primary: Part 1: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma Following a Single Oral Dose…
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib — 48800; 49700 hour*nanogram per…
Moderate Hepatic Impairment
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan — 22500; 14800 ng*hr/mL
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Hour 0 to 24 (AUC [0-24]) Hours of LOXO-305 — 55100; 51900; 59900 hour*nanograms per milliliter
Healthy Volunteers
Primary: Part 1: Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of LOXO-305 — 4000; 4100 nanogram per milliliter (ng/mL)
Healthy · Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Pirtobrutinib — 4240; 4410; 4140; 3270 nanogram per milliliter (ng/mL)
Sickle Cell Disease
Primary: GBT021601 Concentration in Whole Blood and Plasma at Predose — NA; NA Microgram/ milliliter (mcg/mL)
Sepsis · Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Number of Participants With Adverse Events — 3; 4; 5; 4 Participants
Drug-Drug Interaction · Heathy Volunteer
Primary: Cmax for Midazolam, 1-hydroxymidazolam, Following Single Doses of the Parent Drug — 50482.44; 53345.17; 46510.23; 12695.07 pg/mL
Healthy Volunteers · Chronic Kidney Disease
Primary: Effect of RBT-9 on Plasma Ferritin Levels — -9.83; 7.66; 39.37 Percent change from baseline
Healthy
Primary: Cmax of Zavegepant in Plasma Following Single Dose of Zavegepant 10 mg IN — 20.32 nanogram per milliliter (ng/mL)
Advanced Solid Tumors
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 0; 3 Number of participants
Healthy Volunteer Study · Opioid-use Disorder
Primary: Proportion of Participants With TEAEs — 1; 1; 2; 0 Participants